ORYZON Finalist at the 2025 European Lifestars Awards
In the Category Post-IPO Raise of the Year.
Oryzon Genomics S.A., Oryzon Genomics, S.A. (ISIN Code: ES0167733015, Ticker: ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, today announced that it has been selected as a Finalist in the 2025 European Lifestars Awards in the category Post-IPO Raise of the Year for the European Mediterranean region.
The Lifestars Awards bring together leading figures from across the European life sciences industry, including companies, investors, and investment banks, to celebrate outstanding achievements. These annual awards recognize the individuals, teams, and organizations driving innovation, advancing healthcare solutions, and shaping the future of the sector. For more information about these awards, please visit https://informaconnect.com/european-lifestars-awards/
Winners will be announced at the in-person awards ceremony on Monday, November 17, at City Central at the HAC in London.
The nomination highlights the successful completion of a €30 million capital increase in a highly challenging market environment. The financing involved the issuance of 12.76 million new shares at €2.35 per share, representing a 15.44% discount to the 5-day volume-weighted average price (VWAP) of €2.779 and a 19.38% discount to the April 22, 2025, closing price of €2.915. Structured as straight equity with no warrants attached, the offering was met with strong demand and was significantly oversubscribed. A U.S.-based institutional investor anchored the round with a €15 million order, while additional participation came from investors across the U.S., Europe, and Spain. The capital raise was capped at €30 million by the company’s Board of Directors. Since completion, Oryzon’s shares have consistently traded 20–25% above the placement price, underscoring investor confidence and robust aftermarket support.
Desde su cierre, las acciones de Oryzon han cotizado de forma consistente entre un 20 % y un 25 % por encima del precio de colocación, reflejando la confianza del mercado y un sólido respaldo en el aftermarket.
Maxim (U.S.), All-Invest (EU/UK), and Singular Bank (Spain) acted as bookrunners. Banco Sabadell, S.A. acted as the Settlement and Technical Pre-financing Agent for the Capital Increase, while Gómez-Acebo & Pombo Abogados, S.L.P. (Spanish law) and Gibson, Dunn & Crutcher LLP (U.S. law) served as legal advisors to the Company, and Loeb & Loeb LLP acted as U.S. legal counsel to Maxim Group LLC.